New antibody EPI-326 enters first human tests for Hard-to-Treat cancers
NCT ID NCT07462377
First seen Mar 19, 2026 · Last updated Jun 23, 2026 · Updated 19 times
Summary
This early-phase study is testing a new drug called EPI-326 in people with advanced lung cancer (with EGFR mutations) or head & neck cancer. EPI-326 is a bispecific antibody designed to target cancer cells more precisely. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Astera Cancer Care
RECRUITINGEast Brunswick, New Jersey, 08816, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MD Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START Los Angeles
RECRUITINGLos Angeles, California, 90025, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START New York Long Island
RECRUITINGLake Success, New York, 11042, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sarah Cannon and HCA Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
South Texas Accelerated Research Therapeutics (START)
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EPI-326 (a bispecific antibody given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for certain lung and head & neck cancers driven by EGFR mutations.
What could go wrong
This is a very early Phase 1 trial with only 110 people, focused on safety and dosing. It is too soon to know if EPI-326 will be effective or have serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.